Comment on the use of the cre/loxP recombinase system for gene therapy vectors
Scott, S.D. and Marples, B (2000) Comment on the use of the cre/loxP recombinase system for gene therapy vectors. Gene Therapy, 7 (19). p. 1706. ISSN 0969-7128 (print), 1476-5462 (electronic)Full text not available from this repository.
In the recent editorial 'Radiation to control gene expression', Stackhouse and Buchsbaum1 gave an excellent summary of the published research on the use of radiation to target gene therapy for cancer. They also comment on several issues that will have to be addressed before this approach can have a practical application. In the article, they outline our own work2 on a 'molecular switch' to enhance therapeutic gene expression following a comparatively low induction dose of radiation. Commenting on the use of the cre/loxP recombination system, they state: 'The hypothesis that once cre recombinase is produced it will continue to create a functional therapeutic transcript has not been tested. The durability of expression of the cre gene and the stability of the cre enzyme will be critical determinants for the continued expression of the therapeutic gene'. In fact, the basis of the system we describe obviates the need for the continued expression of cre via the radiation-responsive promoter. Consequently, a brief review of the mechanism we have utilised is appropriate to clarify the situation.
|Additional Information:|| This is a letter to the Gene Therapy journal commenting on an editorial entitled 'Radiation to control gene expression' which was published in Gene Therapy July 2000, Volume 7, Number 13, Pages 1085-1086. doi:10.1038/sj.gt.3301233|
|Uncontrolled Keywords:||gene therapy, cancer, cre/loxP, CMV promoter, DNA, molecular switch|
|Subjects:||R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)|
T Technology > TP Chemical technology
|School / Department / Research Groups:||Medway School of Pharmacy|
|Last Modified:||02 Jul 2012 14:20|
Actions (login required)